ATE292121T1 - Chinazolinderivate - Google Patents
ChinazolinderivateInfo
- Publication number
- ATE292121T1 ATE292121T1 AT99943800T AT99943800T ATE292121T1 AT E292121 T1 ATE292121 T1 AT E292121T1 AT 99943800 T AT99943800 T AT 99943800T AT 99943800 T AT99943800 T AT 99943800T AT E292121 T1 ATE292121 T1 AT E292121T1
- Authority
- AT
- Austria
- Prior art keywords
- compounds
- useful
- prevent
- treat
- well
- Prior art date
Links
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical class N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 201000004624 Dermatitis Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 229940123241 Janus kinase 3 inhibitor Drugs 0.000 abstract 1
- 206010025323 Lymphomas Diseases 0.000 abstract 1
- 208000000453 Skin Neoplasms Diseases 0.000 abstract 1
- 206010042496 Sunburn Diseases 0.000 abstract 1
- 206010052779 Transplant rejections Diseases 0.000 abstract 1
- 230000001506 immunosuppresive effect Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000005855 radiation Effects 0.000 abstract 1
- 201000000849 skin cancer Diseases 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/93—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
- C07D239/96—Two oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9736598P | 1998-08-21 | 1998-08-21 | |
| US9735998P | 1998-08-21 | 1998-08-21 | |
| PCT/US1999/019043 WO2000010981A1 (en) | 1998-08-21 | 1999-08-20 | Quinazoline derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE292121T1 true ATE292121T1 (de) | 2005-04-15 |
Family
ID=26793164
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99943800T ATE292121T1 (de) | 1998-08-21 | 1999-08-20 | Chinazolinderivate |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US6313129B1 (de) |
| EP (1) | EP1105378B1 (de) |
| JP (1) | JP2002523403A (de) |
| KR (1) | KR20010089171A (de) |
| AT (1) | ATE292121T1 (de) |
| AU (1) | AU5682799A (de) |
| CA (1) | CA2342503A1 (de) |
| DE (1) | DE69924500T2 (de) |
| HU (1) | HUP0103386A3 (de) |
| IL (1) | IL141434A0 (de) |
| MX (1) | MXPA01001893A (de) |
| NO (1) | NO20010887L (de) |
| WO (1) | WO2000010981A1 (de) |
Families Citing this family (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
| AU3951899A (en) | 1998-06-19 | 2000-01-05 | Pfizer Products Inc. | Pyrrolo(2,3-d)pyrimidine compounds |
| AU5682799A (en) * | 1998-08-21 | 2000-03-14 | Parker Hughes Institute | Quinazoline derivatives |
| JP2003525862A (ja) * | 1999-01-27 | 2003-09-02 | ザ ユニヴァーシティー オブ サウス フロリダ | ヒト癌の治療のためのｓｔａｔ３シグナル伝達の阻害 |
| US6080747A (en) | 1999-03-05 | 2000-06-27 | Hughes Institute | JAK-3 inhibitors for treating allergic disorders |
| US6126917A (en) * | 1999-06-01 | 2000-10-03 | Hadasit Medical Research Services And Development Ltd. | Epidermal growth factor receptor binding compounds for positron emission tomography |
| OA12118A (en) | 1999-12-10 | 2006-05-04 | Pfizer Prod Inc | PyrroloÄ2,3-dÜpyrimidine compounds. |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| OA12292A (en) | 2000-06-26 | 2003-11-11 | Pfizer Prod Inc | PyrroloÄ2,3-dÜpyrimidine compounds as immunosuppressive agents. |
| AU2001278609B2 (en) | 2000-08-21 | 2005-04-14 | Astrazeneca Ab | Quinazoline derivatives |
| US20040052762A1 (en) * | 2001-09-10 | 2004-03-18 | Hua Yu | Stat3 agonists and antagonists and therapeutic uses thereof |
| PL359920A1 (en) * | 2000-09-20 | 2004-09-06 | Merck Patent Gmbh | 4-amino-quinazolines |
| AUPR279101A0 (en) * | 2001-01-30 | 2001-02-22 | Cytopia Pty Ltd | Protein kinase signalling |
| HN2002000067A (es) * | 2001-03-23 | 2003-10-24 | Bayer Healthcare Llc | Inhibidores de la rho - quinasa. |
| PE20020958A1 (es) * | 2001-03-23 | 2002-11-14 | Bayer Corp | Inhibidores de la rho-quinasa |
| SE0101675D0 (sv) | 2001-05-11 | 2001-05-11 | Astrazeneca Ab | Novel composition |
| US7301023B2 (en) | 2001-05-31 | 2007-11-27 | Pfizer Inc. | Chiral salt resolution |
| US7829566B2 (en) * | 2001-09-17 | 2010-11-09 | Werner Mederski | 4-amino-quinazolines |
| GB0122914D0 (en) * | 2001-09-22 | 2001-11-14 | Univ Nottingham | Modulation of stat activity |
| AU2002362030A1 (en) | 2001-11-27 | 2003-06-10 | Fred Hutchinson Cancer Research Center | Methods for inhibiting deacetylase activity |
| EP1465900B1 (de) * | 2002-01-10 | 2008-05-14 | Bayer HealthCare AG | Rho-kinase inhibitoren |
| MXPA04007191A (es) * | 2002-01-23 | 2005-03-31 | Bayer Pharmaceuticals Corp | Derivados de pirimidina como inhibidores de rho-quinasa. |
| CA2473910C (en) * | 2002-01-23 | 2011-03-15 | Bayer Pharmaceuticals Corporation | Pyrimidine derivatives as rho-kinase inhibitors |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| US7645878B2 (en) * | 2002-03-22 | 2010-01-12 | Bayer Healthcare Llc | Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof |
| US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
| EP1521747B1 (de) | 2002-07-15 | 2018-09-05 | Symphony Evolution, Inc. | Modulatoren von rezeptor-typ-kinase und anwendungsverfahren |
| IL166241A0 (en) | 2002-07-29 | 2006-01-15 | Rigel Pharmaceuticals Inc | Method of treating or preventing autoimmune diseases with 2,4-pyrimidinedinediamine compounds |
| US7563810B2 (en) | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
| US8034831B2 (en) | 2002-11-06 | 2011-10-11 | Celgene Corporation | Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies |
| WO2004047843A1 (en) | 2002-11-26 | 2004-06-10 | Pfizer Products Inc. | Method of treatment of transplant rejection |
| KR20050084224A (ko) * | 2002-12-09 | 2005-08-26 | 더 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 야누스 티로신 키나제 3을 선택적으로 저해하는 방법 |
| US7638122B2 (en) * | 2003-03-07 | 2009-12-29 | University Of South Florida | Stat3 antagonists and their use as vaccines against cancer |
| GB0309850D0 (en) | 2003-04-30 | 2003-06-04 | Astrazeneca Ab | Quinazoline derivatives |
| US8309562B2 (en) | 2003-07-03 | 2012-11-13 | Myrexis, Inc. | Compounds and therapeutical use thereof |
| CA2531327A1 (en) | 2003-07-03 | 2005-01-13 | Myriad Genetics, Inc. | Compounds and therapeutical use thereof |
| GB0317665D0 (en) | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Qinazoline derivatives |
| ES2421139T3 (es) | 2003-07-30 | 2013-08-29 | Rigel Pharmaceuticals, Inc. | Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias |
| WO2005026150A1 (en) | 2003-09-16 | 2005-03-24 | Astrazeneca Ab | Quinazoline derivatives as tyrosine kinase inhibitors |
| EP2210607B1 (de) | 2003-09-26 | 2011-08-17 | Exelixis Inc. | N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamid zur Behandlung von Krebs |
| GB0326459D0 (en) | 2003-11-13 | 2003-12-17 | Astrazeneca Ab | Quinazoline derivatives |
| US7626030B2 (en) | 2004-01-23 | 2009-12-01 | Amgen Inc. | Compounds and methods of use |
| WO2005070891A2 (en) * | 2004-01-23 | 2005-08-04 | Amgen Inc | Compounds and methods of use |
| MX2007006230A (es) | 2004-11-30 | 2007-07-25 | Amgen Inc | Quinolinas y analogos de quinazolinas y su uso como medicamentos para tratar cancer. |
| EP1844023A1 (de) * | 2004-12-31 | 2007-10-17 | Sk Chemicals Co., Ltd. | Chinazolinderivate zur behandlung und prävention von diabetes und obesitas |
| US8258145B2 (en) * | 2005-01-03 | 2012-09-04 | Myrexis, Inc. | Method of treating brain cancer |
| CA2592900A1 (en) | 2005-01-03 | 2006-07-13 | Myriad Genetics Inc. | Nitrogen containing bicyclic compounds and therapeutical use thereof |
| US7884109B2 (en) * | 2005-04-05 | 2011-02-08 | Wyeth Llc | Purine and imidazopyridine derivatives for immunosuppression |
| BRPI0610514A2 (pt) * | 2005-04-05 | 2016-11-16 | Pharmacopeia Inc | composto, composição farmacêutica, e, método de tratamento de um distúrbio |
| JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
| US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| WO2006133426A2 (en) | 2005-06-08 | 2006-12-14 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| ES2354457T3 (es) | 2005-09-20 | 2011-03-15 | Astrazeneca Ab | Compuestos de 4-(1h-indazol-5-il-amino)-quinazolina como inhibidores del receptor erbb de la tirosina quinasa para el tratamiento del cáncer. |
| US7989459B2 (en) * | 2006-02-17 | 2011-08-02 | Pharmacopeia, Llc | Purinones and 1H-imidazopyridinones as PKC-theta inhibitors |
| US20090281075A1 (en) * | 2006-02-17 | 2009-11-12 | Pharmacopeia, Inc. | Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors |
| WO2007098507A2 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| TW200831104A (en) * | 2006-10-04 | 2008-08-01 | Pharmacopeia Inc | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
| US7902187B2 (en) * | 2006-10-04 | 2011-03-08 | Wyeth Llc | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
| TW200837064A (en) | 2006-10-04 | 2008-09-16 | Pharmacopeia Inc | 8-substituted 2-(benzimidazolyl)purine derivatives for immunosuppression |
| EP1921070A1 (de) | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung |
| US20080119496A1 (en) * | 2006-11-16 | 2008-05-22 | Pharmacopeia Drug Discovery, Inc. | 7-Substituted Purine Derivatives for Immunosuppression |
| JP5377332B2 (ja) | 2007-02-06 | 2013-12-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 二環式へテロ環、それらの化合物を含む薬剤、その使用及びその製法 |
| DE102008012435A1 (de) * | 2008-02-29 | 2009-09-03 | Schebo Biotech Ag | Neue Pharmazeutika, Verfahren zu ihrer Herstellung und ihre Verwendung in der Therapie |
| AU2008319366B2 (en) * | 2007-10-29 | 2012-03-01 | Amgen Inc. | Benzomorpholine derivatives and methods of use |
| WO2009098061A1 (de) | 2008-02-07 | 2009-08-13 | Boehringer Ingelheim International Gmbh | Spirocyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| HRP20170317T1 (hr) | 2008-02-15 | 2017-04-21 | Rigel Pharmaceuticals, Inc. | Spojevi pirimidin-2-amina i njihova uporaba kao inhibitora jak kinaza |
| US8063058B2 (en) | 2008-04-16 | 2011-11-22 | Portola Pharmaceuticals, Inc. | Inhibitors of syk and JAK protein kinases |
| US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
| BRPI0910668A2 (pt) | 2008-04-22 | 2019-09-24 | Portola Pharmaceutiacals Inc | inibidores de proteína quinases |
| MX2010012442A (es) | 2008-05-13 | 2011-10-11 | Astrazeneca Ab | Sal de fumarato de 4-(3-cloro-2-fluoroanilino)-7-metoxi-6-{[1-(n-m etilcarbamoilmetil) piperidin-4-il]oxi}quinazolina. |
| EP2313397B1 (de) | 2008-08-08 | 2016-04-20 | Boehringer Ingelheim International GmbH | Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| RS53382B (sr) | 2008-08-20 | 2014-10-31 | Zoetis Llc | Jedinjenja pirol [2,3-d]pirimidina |
| KR101361027B1 (ko) | 2008-11-28 | 2014-02-11 | 코와 가부시키가이샤 | 피리딘-3-카르복시아미드 유도체 |
| TW201920110A (zh) | 2009-01-16 | 2019-06-01 | 美商艾克塞里克斯公司 | 包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途 |
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| KR20130094710A (ko) | 2010-04-14 | 2013-08-26 | 어레이 바이오파마 인크. | Ｊａｋ 키나아제의 억제제로서 5,7-치환된-이미다조［1,2-ｃ］피리미딘 |
| EP2975027A1 (de) | 2010-11-01 | 2016-01-20 | Portola Pharmaceuticals, Inc. | Nicotinamide als jak-kinasemodulatoren |
| WO2013025628A1 (en) | 2011-08-15 | 2013-02-21 | Ligand Pharmaceuticals Incorporated | Janus kinase inhibitor compounds and methods |
| SG11201401342VA (en) | 2011-10-12 | 2014-09-26 | Array Biopharma Inc | 5,7-substituted-imidazo[1,2-c]pyrimidines |
| EP2782579B1 (de) | 2011-11-23 | 2019-01-02 | Portola Pharmaceuticals, Inc. | Pyrazinkinaseinhibitoren |
| WO2014013014A1 (en) | 2012-07-18 | 2014-01-23 | Fundació Privada Centre De Regulació Genòmica (Crg) | Jak inhibitors for activation of epidermal stem cell populations |
| WO2014058921A2 (en) | 2012-10-08 | 2014-04-17 | Portola Pharmaceuticals, Inc. | Substituted pyrimidinyl kinase inhibitors |
| KR20170090476A (ko) | 2014-12-05 | 2017-08-07 | 어레이 바이오파마 인크. | 야누스 키나제 저해제로서의 4,6-치환된-피라졸로[1,5-a]피라진 |
| US10646465B2 (en) | 2015-12-17 | 2020-05-12 | Biokine Therapeutics Ltd. | Small molecules against cancer |
| US11129824B2 (en) | 2015-12-17 | 2021-09-28 | Biokine Therapeutics Ltd. | Small molecules for inhibiting chemokine activity and/or cancer cells growth |
| WO2018041989A1 (en) | 2016-09-02 | 2018-03-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosing and treating refractory celiac disease type 2 |
| US10759865B2 (en) | 2017-08-22 | 2020-09-01 | Eyal Levit | Treatment of diabetes mellitus |
| NL2022471B1 (en) | 2019-01-29 | 2020-08-18 | Vationpharma B V | Solid state forms of oclacitinib |
| US12698289B2 (en) | 2019-02-25 | 2026-08-04 | Henan Medinno Pharmaceutical Technology Co., Ltd. | Solid forms of pharmaceutically acceptable salts of (S)-(2-ethyl-5-fluoro-4-hydroxyphenyl)-1H-indazol-3-yl)-4,6-dihydropyrrolo[3,4-d]imidazol-5(1H)-yl)(3-hydroxypyrrolidin-1-yl)methanone as JAK inhibitors |
| KR102873783B1 (ko) | 2019-02-25 | 2025-10-21 | 메디노 파마슈티컬 테크놀로지 (주하이) 컴퍼니 리미티드 | Jak 억제제 화합물 및 그 사용 |
| WO2020201362A2 (en) | 2019-04-02 | 2020-10-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of predicting and preventing cancer in patients having premalignant lesions |
| WO2020212395A1 (en) | 2019-04-16 | 2020-10-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels |
| CA3090315C (en) | 2019-05-15 | 2023-09-19 | Biokine Therapeutics Ltd. | 8-phenoxy-quinolinone derivatives for treating cancer, inhibiting chemokine activity and/or inducing cell death |
| CN112707846B (zh) * | 2019-10-25 | 2023-04-21 | 成都伊诺达博医药科技有限公司 | 一种达克替尼关键中间体的制备方法 |
| US20250283174A1 (en) | 2022-05-16 | 2025-09-11 | Institut National de la Santé et de la Recherche Médicale | Methods for assessing the exhaustion of hematopoietic stem cells induced by chronic inflammation |
| WO2026093435A1 (en) | 2024-10-31 | 2026-05-07 | Institut National de la Santé et de la Recherche Médicale | Use of jak inhibitors for enhancing the potency of immunotherapy in the treament of cancer |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3985749A (en) * | 1975-12-22 | 1976-10-12 | Eastman Kodak Company | Process for preparation of 4-aminoquinazoline |
| JPS5538325A (en) | 1978-09-11 | 1980-03-17 | Sankyo Co Ltd | 4-anilinoquinazoline derivative and its preparation |
| US4343940A (en) * | 1979-02-13 | 1982-08-10 | Mead Johnson & Company | Anti-tumor quinazoline compounds |
| US5710158A (en) | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| US5728536A (en) | 1993-07-29 | 1998-03-17 | St. Jude Children's Research Hospital | Jak kinases and regulation of Cytokine signal transduction |
| US5792771A (en) | 1992-11-13 | 1998-08-11 | Sugen, Inc. | Quinazoline compounds and compositions thereof for the treatment of disease |
| US5712395A (en) * | 1992-11-13 | 1998-01-27 | Yissum Research Development Corp. | Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis |
| US5656643A (en) * | 1993-11-08 | 1997-08-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| GB9510757D0 (en) * | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
| US5705625A (en) * | 1994-12-15 | 1998-01-06 | The Johns Hopkins University School Of Medicine | Nucleic Acid Encoding novel protein tyrosine kinase |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| JPH11507052A (ja) | 1995-06-07 | 1999-06-22 | スージェン・インコーポレーテッド | キナゾリンおよび医薬組成物 |
| US5798374A (en) | 1995-06-07 | 1998-08-25 | Sugen Inc. | Methods of inhibiting phosphatase activity and treatment of disorders associated therewith |
| WO1997003358A1 (en) | 1995-07-07 | 1997-01-30 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Method of identifying inhibitors of the jak-stat signal transduction pathway |
| GB9514265D0 (en) * | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
| CA2242425C (en) * | 1996-02-13 | 2006-07-18 | Zeneca Limited | Quinazoline derivatives as vegf inhibitors |
| NZ331191A (en) * | 1996-03-05 | 2000-03-27 | Zeneca Ltd | 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof |
| GB9607729D0 (en) | 1996-04-13 | 1996-06-19 | Zeneca Ltd | Quinazoline derivatives |
| JP2004504259A (ja) * | 1998-06-30 | 2004-02-12 | パーカー ヒューズ インスティテュート | Ｊａｋ−３インヒビターを用いたｃ−ｊｕｎ発現の阻害方法 |
| AU5682799A (en) * | 1998-08-21 | 2000-03-14 | Parker Hughes Institute | Quinazoline derivatives |
| US6080747A (en) * | 1999-03-05 | 2000-06-27 | Hughes Institute | JAK-3 inhibitors for treating allergic disorders |
| US20030149045A1 (en) * | 1999-08-20 | 2003-08-07 | Fatih M Uckun | Therapeutic compounds |
-
1999
- 1999-08-20 AU AU56827/99A patent/AU5682799A/en not_active Abandoned
- 1999-08-20 IL IL14143499A patent/IL141434A0/xx unknown
- 1999-08-20 CA CA002342503A patent/CA2342503A1/en not_active Abandoned
- 1999-08-20 WO PCT/US1999/019043 patent/WO2000010981A1/en not_active Ceased
- 1999-08-20 HU HU0103386A patent/HUP0103386A3/hu unknown
- 1999-08-20 AT AT99943800T patent/ATE292121T1/de not_active IP Right Cessation
- 1999-08-20 DE DE69924500T patent/DE69924500T2/de not_active Expired - Fee Related
- 1999-08-20 JP JP2000566255A patent/JP2002523403A/ja active Pending
- 1999-08-20 EP EP99943800A patent/EP1105378B1/de not_active Expired - Lifetime
- 1999-08-20 KR KR1020017002230A patent/KR20010089171A/ko not_active Withdrawn
- 1999-08-20 US US09/378,093 patent/US6313129B1/en not_active Expired - Fee Related
- 1999-08-20 MX MXPA01001893A patent/MXPA01001893A/es unknown
-
2001
- 2001-02-21 NO NO20010887A patent/NO20010887L/no not_active Application Discontinuation
- 2001-03-19 US US09/812,098 patent/US6495556B2/en not_active Expired - Fee Related
- 2001-05-16 US US09/858,824 patent/US6469013B2/en not_active Expired - Fee Related
-
2003
- 2003-11-17 US US10/715,773 patent/US20060276491A9/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL141434A0 (en) | 2002-03-10 |
| US20010044442A1 (en) | 2001-11-22 |
| NO20010887L (no) | 2001-04-23 |
| HUP0103386A2 (hu) | 2002-04-29 |
| MXPA01001893A (es) | 2002-04-24 |
| DE69924500T2 (de) | 2006-02-09 |
| US20060276491A9 (en) | 2006-12-07 |
| WO2000010981A1 (en) | 2000-03-02 |
| US20020042513A1 (en) | 2002-04-11 |
| US6313129B1 (en) | 2001-11-06 |
| JP2002523403A (ja) | 2002-07-30 |
| CA2342503A1 (en) | 2000-03-02 |
| NO20010887D0 (no) | 2001-02-21 |
| EP1105378B1 (de) | 2005-03-30 |
| DE69924500D1 (de) | 2005-05-04 |
| HUP0103386A3 (en) | 2002-07-29 |
| US20040192711A1 (en) | 2004-09-30 |
| WO2000010981A9 (en) | 2002-08-29 |
| AU5682799A (en) | 2000-03-14 |
| US6469013B2 (en) | 2002-10-22 |
| KR20010089171A (ko) | 2001-09-29 |
| EP1105378A1 (de) | 2001-06-13 |
| US6495556B2 (en) | 2002-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69924500D1 (de) | Chinazolinderivate | |
| GEP20053424B (en) | Pyrimidine-2,4,6-Trione Metalloproteinase Inhibitors | |
| FI972086A7 (fi) | Parannetun monilääkeresistenssiaktiivisuuden omaavat uudet aminohappoj ohdokset | |
| NO20014560L (no) | Quinasoliner og terapautisk anvendelse derav | |
| NO20100777L (no) | Kinazolinoner, slike forbindelser for anvendelse som medikament, farmasoytiske preparater inneholdende slike samt anvendelse av slike for fremstilling av medikament for behandling av sykdom | |
| YU176191A (sh) | Derivati hinazolina za pojačavanje antitumorne aktivnosti | |
| TR199900048T2 (xx) | Protein tirozin kinaz inhibit�rleri olarak bisiklik heteroaromatik bile�ikler | |
| DE60231439D1 (de) | Mitotische kinesinhemmer | |
| DE60234278D1 (de) | Mitotische kinesin-hemmer | |
| DK1438052T3 (da) | Quinazolin-4-oner af inhibitorer som human phosphatidylinositol 3-kinase delta | |
| NO20014303L (no) | JAK-3-inhibitorer for behandling av allergiske lidelser | |
| UY25074A1 (es) | Inhibidores de la farnesil proteina transferasa | |
| DE60329990D1 (de) | Mitotische kinesin-hemmer | |
| IS2114B (is) | Kínasólínafleiður til að meðhöndla æxli | |
| EP0939627A4 (de) | Pentafluorobenzensulfonamide und analoge | |
| PA8606201A1 (es) | DERIVADOS DE PIRROLO[3,4-c) PIRAZOL ACTIVOS COMO INHIBIDORES DE QUINASA, PROCESO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN | |
| IL142066A0 (en) | Arylsulfonanilide urea derivatives and pharmaceutical compositions containing the same | |
| ATE527254T1 (de) | Mit imidazol enthaltenden sekundären aminen substituierte benzopyran-derivate, deren herstellung und diese enthaltende pharmazeutische zubereitungen | |
| DE69426334D1 (de) | Parenterales Busulfan zur Behandlung von malignen Krankheiten | |
| UY28130A1 (es) | Compuestos de indazol y composiciones farmaceuticaspara inhibr proteinquinasas, y procedimientos para su uso. | |
| PT1235571E (pt) | Utilizacao de melatonina para o tratamento da alopecia androgenetica e difusa do tipo feminino | |
| BR0208447A (pt) | Inibidores de cinase dependente de ciclina como agente anticâncer | |
| ATE355288T1 (de) | Verbindungen und therapeutische methoden | |
| UA84954C2 (ru) | Конденсированные пиримидоны, пригодные для лечения и профилактики злокачественного новообразования | |
| MXPA02010759A (es) | Derivados del acido (2-oxindol-3-ilidenil) acetico y su uso como inhibidores de la proteina quinasa. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |